Johann Wolfgang Goethe University Hospital
kgu.deTotal trials
159
Active
5
Phase 3
10
Total enrollment
1,183,347
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| red blood cell transfusion trigger | — | — | — | — | — | 1 | |
| NK-92/5.28.z | — | — | — | — | — | 1 | |
| Ezabenlimab | — | — | — | — | — | 1 |
Next readouts
- 2025-06-30
- 2027-12-31
Top conditions
- Heart Failure6
- Ataxia Telangiectasia6
- Allergic Asthma5
- Bronchiolitis Obliterans4
- Coronary Artery Disease4
- House Dust Mite Allergy3
- Asthma3
- Allergy3
Frequently asked questions about Johann Wolfgang Goethe University Hospital
- How many clinical trials does Johann Wolfgang Goethe University Hospital have on ClinicalTrials.gov?
- Johann Wolfgang Goethe University Hospital is listed as the lead sponsor on 159 clinical trials in ClinicalTrials.gov, 5 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Johann Wolfgang Goethe University Hospital's trials are in Phase 3?
- 10 of Johann Wolfgang Goethe University Hospital's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does Johann Wolfgang Goethe University Hospital focus on?
- Johann Wolfgang Goethe University Hospital's most-studied conditions on ClinicalTrials.gov are Heart Failure, Ataxia Telangiectasia, Allergic Asthma, Bronchiolitis Obliterans, Coronary Artery Disease.
- When are Johann Wolfgang Goethe University Hospital's next clinical trial readouts?
- Johann Wolfgang Goethe University Hospital has 2 upcoming primary-completion readouts tracked here; the soonest is “Liberal Transfusion Strategy in Elderly Patients”, expected around 2025-06-30.